Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?

Giuseppe Buono(Federico II University Hospital), Fabio Puglisi(University of Udine), Grazia Arpino(University of Naples Federico II), Lorenzo Gerratana(National Cancer Institute), Carla Corvaja(University of Udine), Mario Giuliano(Regione Campania), Nicoletta Provinciali(Ente Ospedaliero Ospedali Galliera), Lucia Del Mastro(Ospedale Policlinico San Martino), Sabino De Placido, Debora Basile(University of Udine), Michela Bulfoni(University of Udine), Massimo Cristofanilli(Cornell University)
Cancer Treatment Reviews
January 11, 2019
10.1016/j.ctrv.2019.01.004
Cited by 124

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830